Phase II Study of the Src Kinase Inhibitor Saracatinib (AZD0530) in Metastatic Melanoma

Por Gangadhar, Tara C., Clark, Joseph I., Karrison, Theodore, Gajewski, Thomas F.
Publicado em 2012

Complications of sequential immunotherapy in metastatic melanoma

Por Bufalino, Shams, Singh, Shruti, Borys, Ewa, Hutchens, Kelli, Le Poole, I Caroline, Clark, Joseph I
Publicado no J Immunother Cancer (2015)

Thrombotic microangiopathy associated with sunitinib, a VEGF inhibitor, in a patient with factor V Leiden mutation

Por Levey, Seth A., Bajwa, Randeep S., Picken, Maria M., Clark, Joseph I., Barton, Kevin, Leehey, David J.
Publicado no NDT Plus (2008)

Combination Trimodality Therapy Using Vismodegib for Basal Cell Carcinoma of the Face

Por Block, Alec M., Alite, Fiori, Diaz, Aidnag Z., Borrowdale, Richard W., Clark, Joseph I., Choi, Mehee
Publicado no Case Rep Oncol Med (2015)

A phase II trial of biweekly gemcitabine and paclitaxel with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN): SWOG study S0329

Por Malhotra, Binu, Moon, James, Kucuk, Omar, Clark, Joseph I, Urba, Susan G, Wolf, Gregory T, Worden, Francis P
Publicado no Head Neck (2014)

A University of Chicago Consortium Phase II Trial of SB-715992 in Advanced Renal Cell Cancer

Por Lee, Richard T., Beekman, Kathleen E., Hussain, Maha, Davis, Nancy B., Clark, Joseph I., Thomas, Sachdev P., Nichols, Katherine F., Stadler, Walter M.
Publicado em 2008

A PHASE II STUDY OF GEMCITABINE AND CAPECITABINE IN PATIENTS WITH ADVANCED RENAL CELL CANCER (RCC): SOUTHWEST ONCOLOGY GROUP STUDY S0312

Por Van Veldhuizen, Peter J., Hussey, Michael, Lara, Primo N., Mack, Philip C., Gandour-Edwards, Regina, Clark, Joseph I., Lange, Marianne K., Crawford, E. David
Publicado em 2009

PHASE I ADJUVANT RADIATION WITH DOCETAXEL IN HIGH RISK HEAD AND NECK CANCER

Por Clark, Joseph I., Eisner, Robert M., Hofmeister, Craig, Norton, John, Thomas, Sachdev, Choudhury, Abdul, Petruzzelli, Guy, Lathers, Deanne, Young, M. Rita I., Lau, Ann, Emami, Bahman
Publicado em 2009

Overall survival of metastatic melanoma patients treated with HD IL-2 followed by immune checkpoint blockade of the CTLA-4 or the PD-1 pathways: analysis of data on the current use...

Por Wong, Michael KK, Morse, Michael A, McDermott, David F, Clark, Joseph I, Kaufman, Howard L, Daniels, Gregory A, Perritt, Jessica C, Hua, Hong, Aung, Sandra
Publicado no J Immunother Cancer (2015)

Durability of responses in patients with metastatic renal cell carcinoma treated with high dose interleukin-2 (HD IL-2)

Por Clark, Joseph I, Morse, Michael A, Wong, Michael KK, McDermott, David F, Kaufman, Howard L, Daniels, Gregory A, Perritt, Jessica C, Hua, Hong, Aung, Sandra
Publicado no J Immunother Cancer (2015)

Phase II Study of Erlotinib in Patients With Locally Advanced or Metastatic Papillary Histology Renal Cell Cancer: SWOG S0317

Por Gordon, Michael S., Hussey, Michael, Nagle, Raymond B., Lara, Primo N., Mack, Philip C., Dutcher, Janice, Samlowski, Wolfram, Clark, Joseph I., Quinn, David I., Pan, Chong-Xian, Crawford, David
Publicado em 2009

Phase II Trial of Combination Thalidomide plus Temozolomide in Patients with Metastatic Malignant Melanoma: Southwest Oncology Group S0508

Por Clark, Joseph I., Moon, James, Hutchins, Laura F., Sosman, Jeffrey A., Kast, W. Martin, Da Silva, Diane M., Liu, P.Y., Thompson, John A., Flaherty, Lawrence E., Sondak, Vernon K.
Publicado em 2010

Efficacy and safety of high-dose interleukin-2 treatment in patients with a history of brain metastases from renal cell carcinoma

Por Chandar, Ashwin, Silk, Ann W, Clark, Joseph I, Daniels, Gregory A, McDermott, David F, Morse, Michael, Wong, Michael KK, Stein, Mark, Mehnert, Janice, Danish, Shabbar, Aung, Sandra, Kaufman, Howard L
Publicado no J Immunother Cancer (2015)

The transfer of genetically engineered lymphocytes in melanoma patients: a Phase I dose escalation study

Por Regan, Courtney, Nishimura, Michael, Le Poole, I Caroline, Godellas, Constantine, Stiff, Patrick, Garrett-Mayer, Elizabeth, Li, Mingli, Shirai, Keisuke, Eby, Jonathan, Embree, Heather, Dropulic, Boro, Clark, Ann Lau, Hutchens, Kelli, Clark, Joseph I
Publicado no J Immunother Cancer (2015)

CCL22 DIVERTS T REGULATORY CELLS AND CONTROLS THE GROWTH OF MELANOMA

Por Klarquist, Jared, Tobin, Kristen, Oskuei, Peyman Farhangi, Henning, Steven W., Fernandez, Manuel F., Dellacecca, Emilia R., Navarro, Flor C., Eby, Jonathan M., Chatterjee, Shilpak, Mehrotra, Shikhar, Clark, Joseph I., Le Poole, I. Caroline
Publicado no Cancer Res (2016)

A Phase II Study of Erlotinib and Bevacizumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Por Cohen, Ezra EW, Davis, Darren W., Karrison, Theodore G, Seiwert, Tanguy Y., Wong, Stuart J., Nattam, Sreenivasa, Kozloff, Mark F., Clark, Joseph I., Yan, Duen-Hwa, Liu, Wen, Pierce, Carolyn, Dancey, Janet E, Stenson, Kerstin, Blair, Elizabeth, Dekker, Allison, Vokes, Everett E
Publicado em 2009

Cytokine Working Group Study of Lymphodepleting Chemotherapy, Interleukin-2, and Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Metastatic Melanoma: Clinical Out...

Por Gunturu, Krishna S., Meehan, Kenneth R., Mackenzie, Todd A., Crocenzi, Todd S., McDermott, David, Usherwood, Edward J., Margolin, Kim A., Crosby, Nancy A., Atkins, Michael B., Turk, Mary Jo, Ahonen, Cory, Fuse, Shinichiro, Clark, Joseph I., Fisher, Jan L., Noelle, Randolph J., Ernstoff, Marc S.
Publicado em 2010

Three Phase II Cytokine Working Group Trials of gp100 (210M) Peptide Plus High-Dose Interleukin-2 in Patients With HLA-A2–Positive Advanced Melanoma

Por Sosman, Jeffrey A., Carrillo, Carole, Urba, Walter J., Flaherty, Lawrence, Atkins, Michael B., Clark, Joseph I., Dutcher, Janet, Margolin, Kim A., Mier, James, Gollob, Jarod, Kirkwood, John M., Panka, David J., Crosby, Nancy A., O’Boyle, Kevin, LaFleur, Bonnie, Ernstoff, Marc S.
Publicado em 2008

A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma

Por Buchbinder, Elizabeth I., Gunturi, Anasuya, Perritt, Jessica, Dutcher, Janice, Aung, Sandra, Kaufman, Howard L., Ernstoff, Marc S., Miletello, Girald P., Curti, Brendan D., Daniels, Gregory A., Patel, Sapna P., Kirkwood, John M., Hallmeyer, Sigrun, Clark, Joseph I., Gonzalez, Rene, Richart, John M., Lutzky, Joe, Morse, Michael A., Sullivan, Ryan J., McDermott, David F.
Publicado no J Immunother Cancer (2016)

Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma

Por Alva, Ajjai, Daniels, Gregory A., Wong, Michael K. K., Kaufman, Howard L., Morse, Michael A., McDermott, David F., Clark, Joseph I., Agarwala, Sanjiv S., Miletello, Gerald, Logan, Theodore F., Hauke, Ralph J., Curti, Brendan, Kirkwood, John M., Gonzalez, Rene, Amin, Asim, Fishman, Mayer, Agarwal, Neeraj, Lowder, James N., Hua, Hong, Aung, Sandra, Dutcher, Janice P.
Publicado no Cancer Immunol Immunother (2016)